Wednesday, October 20, 2021
Cost-sharing waiver set to expire as planned on Dec. 31, 2021
PITTSBURGH (October 20, 2021) – As COVID-19 cases and hospitalizations have declined, Highmark announced today that its cost-sharing waiver for in-network, inpatient COVID-19 treatment will expire as planned on Dec. 31, 2021.
“Highmark’s claims data has shown that the risk of COVID infection and treatment has been significantly reduced with the broad availability of vaccines,” said Dr. David Webster, interim Health Plan Chief Medical Officer for Highmark. “However, COVID is still serious, and we have been waiving cost-sharing, such as deductibles and co-pays, for in-hospital treatment longer than most other insurers to help ensure that members can be treated without facing any financial barriers.”
Members who may require in-hospital treatment for COVID-19 after Dec. 31, 2021 will continue to have coverage for treatment with some cost-sharing, Dr. Webster added.
Additionally, Highmark’s Medicare Advantage members will continue to see no copays for COVID related hospital admissions through the end of 2022.
For more information, visit highmarkanswers.com.
About Highmark Inc.
One of America's leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, Highmark Inc. (the Health Plan) and its affiliated health plans (collectively, the Health Plans) work passionately to deliver high-quality, accessible, understandable, and affordable experiences, outcomes, and solutions to customers. As the fourth-largest overall Blue Cross Blue Shield-affiliated organization, Highmark Inc. and its Blue-branded affiliates proudly cover the insurance needs of more than 6 million members in Pennsylvania, Delaware, West Virginia and New York. Its diversified businesses serve group customer and individual needs across the United States through dental insurance and other related businesses. For more information, visit www.highmark.com.
For more information, contact